Stocks @ Night is a daily newsletter delivered after hours, giving you the first information about tomorrow and the last information about today. Sign up for free to receive it straight to your inbox. Here’s what CNBC television producers were looking at Thursday and what they’re looking at for Friday’s session. Thursday Night Stock Stories… Apple We’ll continue to monitor Apple stock and start the full analysis with Frank Holland on “Worldwide Exchange” starting at 5 a.m. ET. The tech giant reported better-than-expected earnings on Thursday. Chief Executive Officer Tim Cook said he was optimistic about the outlook, mainly due to strong sales of the iPhone 17. He said the company’s sales could be “unexpected.” Apple rose nearly 3% in after-hours trading. Including tonight’s gains, the stock is up about 12% since the beginning of the year. Ignoring the company’s weak start to the year, the stock is up about 30% in six months. Energy giant ExxonMobil reported this morning. The numbers will be released on Squawk Box, with full coverage from Becky Quick, Joe Kernen and Andrew Ross Sorkin, who will share the stock reaction. CEO Darren Woods will be appearing live from 8am with Becky Quick. ExxonMobil stock has risen about 2% in the three months since the last announcement. The stock is down 7% from its November 22 high. XOM YTD Mountain ExxonMobil Year to Date Share Chevron Chevron also reported during “Squawk Box,” and CEO Mike Wirth will appear on CNBC’s “Squawk on the Street” at 9 a.m. with Carl Quintanilla, David Faber and Jim Cramer. The stock price has remained roughly flat since our last report three months ago. The stock is up 9% from its March 26 high. Oil Over the past three months, Brent crude oil has fallen 11%. WTI crude oil prices have fallen nearly 14% in the past three months. Huntington Ingalls The warship maker reported record revenue of $3.2 billion in the third quarter. “This increase was primarily due to stronger segment performance at Newport News Shipbuilding and Ingalls Shipyard compared to the same period last year,” the company’s earnings statement said. The announcement also said: “We continue to see early signs that targeted investments are helping to build stronger maritime supply chains that support the strengthening of our workforce and the advancement of shipbuilding.” Shares rose 7% on Thursday, hitting a new 52-week high. And the stock continued to rise another 2% in after-hours trading. The stock is up 69% since the beginning of the year. This all comes as President Donald Trump has threatened another nuclear test following Russia’s underwater test of a nuclear drone. HII YTD Mountain Huntington Ingalls Year-to-date Stock Performance Tariff Talk with Tom Rotunno What we learned today: Hershey is one of the latest companies to mitigate the expected impact of tariffs, albeit by a small amount. The candy maker said on an earnings call Thursday that it currently models tariff costs in the range of $160 million to $170 million, a $10 million reduction. The company said the change reflects Canada’s retaliatory tariff reduction. Hershey is down 10% over the past three months, but is up 1% year-to-date. It has been negative for four consecutive weeks, and fell more than 8% in October. Candy rival Mondelez is down 11% over the past three months and 3% year-to-date. Both companies are components of the Consumer Staples Select Sector SPDR Fund (XLP). The fund is down 3% this year and about 5% in the past three months. What we might learn tomorrow: The threat of higher tariffs has become a top concern for pharmaceutical companies this year, as the Trump administration considers tariffs on imported drugs and raw materials. Those tariffs are on hold for now, but the administration says they won’t be imposed on companies that invest in U.S. manufacturing. AbbVie reported before the bell Friday and previously said it was “fairly insulated” from the impact of the tariffs. The company has 11 manufacturing locations in the United States and announced plans to invest $10 billion in domestic manufacturing. AbbVie is up almost 30% since the beginning of the year and more than 20% in the past three months. Analysts are generally positive about the stock’s move toward earnings. Of the 31 analysts covering the stock, 61% rate it a Buy or Overweight. 35% are Holds and only 1 is Sell or Underweight. The average price target is $240.28, implying a 5% upside. ABBV YTD Mountain AbbVie stock price year-to-date.
